Publications by authors named "Shiho Yamadera"
Introduction: Nivolumab is an immune checkpoint inhibitor used to treat advanced renal cell carcinoma (RCC). Adrenal insufficiency has been reported as an adverse event associated with nivolumab. We report a case of adrenal insufficiency that occurred more than 1 year after the initiation of nivolumab while patient was still receiving treatment.
View Article and Find Full Text PDFArticle Synopsis
- Lipopolysaccharides (LPS) are known to trigger inflammation by interacting with the TLR4 complex, but the anti-inflammatory effects of linagliptin in TLR4-independent pathways had not been previously explored.
- This study investigated linagliptin's ability to suppress IL-6 production in U937 cells subjected to LPS, using various concentrations of linagliptin and anti-TLR4 antibodies in both serum-rich and serum-free media.
- The findings revealed that linagliptin effectively reduced IL-6 levels in a concentration-dependent manner, demonstrating its potential for mitigating LPS-induced inflammation even in the absence of TLR4 signaling.
Purpose: Dipeptidyl peptidase-4 inhibitors, including linagliptin, prevent inflammation. However, the in vitro effects of linagliptin are unclear. Moreover, although linagliptin inhibits lipopolysaccharide (LPS)-induced inflammation, the anti-inflammatory effects of linagliptin in this context are not concentration-dependent.
View Article and Find Full Text PDFBackground: Atherosclerosis and inflammation are more common in patients with diabetes than in patients without diabetes, and atherosclerosis progression contributes to inflammation. Therefore, anti-inflammatory therapy is important for the prognosis of patients with diabetes. Linagliptin is the only bile-excreted, anti-diabetic oral dipeptidyl peptidase-4 (DPP-4) inhibitor.
View Article and Find Full Text PDFAim: To examine the effects of vitamin E-coated dialyzer on oxidative stress in vitro.
Methods: A dialyzer with a synthetic polymer membrane (APS-11SA) and vitamin E-coated dialyzer (VPS-11SA) were connected to a blood tubing line, and U937 cells were circulated in the device. The circulating fluid was collected at 1, 2, 5, 10, 25, and 50 cycles, which are estimated numbers of passes through the dialyzer.